NanoTemper Technologies

Protein production teams, get ready to move faster and more efficiently to deliver high-quality recombinant proteins! We’re excited to bring you Andromeda X, now with Spectral Shift technology, to help you optimize protein expression for all of your drug discovery workflows. Learn more: https://bit.ly/3whayEf

When screening fragments, it's critical to distinguish true hits from artifacts so you maximize the chances of creating a successful therapeutic. So, what should you consider when choosing hit cut-offs during single-dose screens?     R&D scientist Nathan Adams from NanoTemper shares his insights on identifying true hits with Spectral Shift technology.

G Protein-Coupled Receptors (GPCRs) are well-established as effective drug targets, but their inherent complexity poses significant challenges for binding measurements. Here are four reasons why conventional methods often fall short and why alternative approaches are essential: 1️⃣ GPCRs are membrane proteins: GPCRs are membrane-bound, making them amphipathic and challenging to solubilize. Traditional techniques often fail to maintain their solubility, leading to unreliable results. Advanced methods are required to handle these solubility challenges effectively. 2️⃣ GPCRs have a complex structure: The structural intricacies of GPCRs are difficult to study in isolation. Their dynamic nature means that traditional static analysis techniques can't capture the full picture. Innovative technologies that allow for real-time, structural analysis are needed to better understand these receptors. 3️⃣ GPCRs display intricate modes of action: GPCRs engage in complex signaling pathways, including dimerization, transduction, and three-way interactions. Traditional binding studies can overlook these multifaceted interactions. Comprehensive approaches that account for these complexities are essential for accurate drug targeting. 4️⃣ GPCRs need alternative expression strategies The difficulty in producing GPCRs in high yields leads to reliance on alternative expression systems, often resulting in lower yields and the need for detergent-heavy buffers. This makes it crucial to use methods that maximize receptor production while preserving function. If you're working with GPCRs, how do you currently address the challenges above?

Working on developing your next bispecific antibody? In a recent publication scientists from DTU - Technical University of Denmark describe a comprehensive set of complementary methods to study Bispecific mAbs critical quality attributes (CQAs) including thermal stability and aggregation propensity. Among other tools, their study highlight the value of Prometheus Panta for simultaneous thermal and colloidal stability measurements with high-throughput and very low material consumption, crucial in the developability assessment of bispecifics. The authors state "Importantly, the simultaneous monitoring of aggregation during unfolding, as illustrated in Figure 2, favors in-depth understanding of the antibody behavior and developability profile." Read the publication here: https://lnkd.in/eybphcZY

Hot off the press excitement for #structuralbiology combining NanoTemper Technologies label-free thermal unfolding #nanoDSF with #CryoEM! 🎆 A global team of researchers from Stockholm University, Harvard University, Boston Children's Hospital and Ipsen Bioinnovation just published this exciting work in Nature Portfolio's Communication Chemistry investigating a new botulinum neurotoxin serotype, BoNT/X, with promising therapeutic properties, and how the presence or absence of it's protective partner protein (NTNH) that stabilized the BoNT/X affects potency. Read more about this exciting #research here: https://lnkd.in/g9rfPNv8 #biophysics #protein #toxin #therapeutic #teamwork

I've asked: "Biotech 2020 - 2024: from heaven to hell?" - Now, let's extend our view to 2019 - SURPRISE: it does NOT look like hell. I've used ChatGPT to analyze the quarterly numbers from the companies Waters Corporation, Bio-Techne, Sartorius, Danaher, Agilent, and Thermo Fisher from 2019 to now. These companies provide tools for pharma and biotech - like our company NanoTemper Technologies does. We see 3 phases: 2019 and before: The Pre-Pandemic "normal". I've normalized everything to the 1st quarter in 2019. 2020-2022: The Highs The biotech industry soared during the pandemic. Money flowed like never before. We were in a golden age—innovation, expansion, optimism. It felt like nothing could go wrong. We were all riding high. 2023-2024: The Transition The tide turns. Layoffs in pharma. Biotech is running out of funding. Everyone has to fight hard for every dollar. Some companies are doing well - like Bio-Techne. Some companies suffer, like Agilent. It is a mixed and complex pattern. When I've wrote "we are in a crisis" 2 months ago: Did I miss the big picture? Have I been blinded by the years of hype? Compared to 2019 we are at a high level. Maybe not heaven anymore. But still paradise? How do you interprete the data? #biotechnology #entrepreneurship #startup ————————— I am Philipp - founder, CEO & business angel. My bootstrapped company NanoTemper is a global leader for biophysical tools for biotech. Like my content? Click my name + follow + 🔔

1st summer in our new Headquarters +30°C hot Munich summer. 7 weeks of Bavarian vacations. 4 month in our new HQ. Just delivered fastest drug screening instrument of the world. That means: perfect time to relax and to enjoy some Espresso and ice cream. In this hidden object fun picture you can find: 1x the strongest coffee machine of the world. 2x Philipp’s with long hair. 4x different nations. 42x ice creams. Our NanoTemper Technologies team have had demanding months. Everyone did an awesome job - often until it hurt. We’ve - again - achieved what has been considered as impossible. A huge THANK YOU! We are proud of you! Now is the time to relax and to have fun. As Anjuli says: “Work hard - party harder!” #biotechnology #entrepreneurship #startup ————————— I am Philipp - founder, CEO & business angel. My bootstrapped company NanoTemper is a global leader for biophysical tools for biotech. Like my content? Click my name + follow + 🔔

Olympic record for drug discovery: A 1536 plate measured in 10 minutes. Highest speed of all biophysical instruments. 2 weeks of Olympics in Paris. 2 weeks of exceptional performances & records. The show must go on: We've just delivered our 1st ultra high throughput instrument. It measures a 1536 well plate in record time: 10 minutes including the plate handling steps. It is for drug screening and hit confirmation. It uses our Spectral Shift Technology. It is an optical method. It is in free solution. You want to know more? Please comment with "Dianthus uHTS" #biotechnology #entrepreneurship #startup ————————— I am Philipp - founder, CEO & business angel. My bootstrapped company NanoTemper is a global leader for biophysical tools for biotech. Like my content? Click my name + follow + 🔔

Researchers from the Institute of Plant Science and Microbiology, Universität Hamburg, Germany, unraveled mechanisms of protein-RNA interactions and phase separation, using the Monolith to study glycine-rich RNA binding protein 7 (GRP7). Here are the researchers’ key findings: 💡 GRP7’s RNA Binding: Both the RNA-recognition motif and the glycine-rich RGG-domain are critical for RNA interaction. 💡 Mutation Studies: Our mutation analysis revealed how specific sites within the RGG-domain affect RNA binding. 💡 Phase Separation: We explored GRP7 and its mutants’ liquid–liquid phase separation with and without RNA. 💡 RNA Selectivity: Testing different RNAs highlighted GRP7’s high affinity for various RNA types, indicating minimal selectivity. 💡 RGG-domain’s Role: Crucial for binding longer RNAs and promoting phase separation. Read here the full publication: https://lnkd.in/dWiZFiv7

Biologic scientists – What kind of stability attributes are you looking at to ensure optimal formulation of your candidates? Here are the 3 main attributes that experts like Aaron Frimel from Thermo Fisher Scientific evaluate: 1️⃣ Protein foldedness to ensure proper activity 2️⃣ Formation of soluble aggregates to limit the risk of hyper potency 3️⃣ Presence of sub-visible particles to avoid unintended immunogenicity